40+ results for "technology"
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology Manufacturing of cGMP material for clinical trials is underway IND application remains on track to be filed in 1H 2027 MIRAMAR, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- HCW Biologic
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company’s management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York. 2026 Maxim Growth Summit Conference Details: Format: One-on-one meetings Date: October 12
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a c
KONE Inaugurates India's First Digital Experience Centre in Pune to Advance Digital Innovation
New Centre showcases how AI, connectivity, data and digital solutions are transforming customer experiences and enabling smarter, more connected buildings PUNE, India , Oct. 9, 2026 -- KONE, a global leader in the elevator and escalator industry, today inaugurated India s first KONE Digital Experience Centre (DEC) in Pune, marking an important milestone in its digital transformation journey and commitment to creating exceptional customer experiences through technology, data and innovation. The Centre was jointly inaugurated by Jussi Herlin, Executive Vice Chair, KONE; Philippe Delorme, President and CEO, KONE along with Nandan Nilekani, Co-founder and Chairman of the Board, Infosys.
MIDEA COMPLETES THE ACQUISITION OF ESAOTE
Midea Group marks its commitment to healthcare and innovation by completing the acquisition of Esaote GENOA, Italy , Oct. 9, 2026 -- Esaote S.p.A., a leader in the medical imaging sector, announces the completion of the controlling stake acquisition of its share capital by Midea the Chinese global technology group headquartered in the district of Shunde, Foshan. The transaction is aimed at fostering synergies between Esaote and Midea s Healthcare Division to increase international competitiveness. Esaote will be part of Midea Healthcare and will continue to operate as an independent global medical equipment company, headquartered in Genoa, Italy, with R&D and manufacturing facilities in Italy and the Netherlands.
TRexBio Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the pricing of its initial public offering of 8,333,334 shares of its common stock at an initial public offering price of $14.00 per share. All of the shares are being offered by TRexBio. The gross proceeds from the offering, before deducting
Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced interim data from its Phase 1 clinical trial of ER-100 in three participants with open angle glaucoma (OAG). The data demonstrated that a single intravitreal administrati
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologou
IMUNON to Participate in Upcoming Investor Conferences
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences. Maxim Growth Summit 2026 Date: October 12 - 14, 2026 Location: Hard Rock Hotel, New York, NY Presentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET For more information and a
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce preliminary results from its preclinical study of MB-204 in the Shank3Δex13-16 mouse model , a model associated with Phelan-McDermid sy
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON , Oct. 8, 2026 -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc. , (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions.
Dreame Technology Announces Great Indian Festival 2026 Sale with Its Best-Ever Prices on Smart Home and Personal Care Products
Unmatched offers on select robotic vacuums, wet and dry vacuum cleaners, cordless stick vacuums, and its personal care range on Amazon NEW DELHI , Oct. 8, 2026 -- With the Amazon Great Indian Festival just around the corner, Dreame Technology, a global leader in smart home innovation, is bringing its smart home and personal care range to consumers with exclusive offers on Amazon India. Starting today , the sale will feature attractive deals across Dreame s portfolio of robotic vacuums, wet and dry vacuum cleaners, cordless stick vacuums and grooming solutions, giving consumers an opportunity to upgrade their everyday routines with smart technology. The products will also be available at the same festive prices on the Dreame India website , Croma and Reliance Retail.
Bio Usawa Takes Major Step Toward Building a Self-Sustaining Biotechnology Ecosystem in Africa
The establishment of Botswana subsidiary strengthens regional capacity and expands access to affordable biologics SAN FRANCISCO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology today announced the launch of Bio Usawa Biotech Botswana (Pty) Ltd, marking an important milestone in the company’s mission to build a self-sustaining biotechnology ecosystem across Africa and expand access to safe, effective, and affordable biologic medicines. The Botswana subsidiary expands Bio Usawa’s interna
SEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma Study
Nature Communications publication provides new evidence that Vaccinex’s pepinemab may help reshape the tumor environment to support a coordinated immune attack on cancer, potentially complementing checkpoint inhibitors and other immunotherapies ROCHESTER, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. a clinical-stage biotechnology company pioneering a differentiated approach to treating Cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone with 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor (CPI
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten
CHARM Therapeutics announces first patient dosed and first cohort fully enrolled in its Phase I/II clinical trial of CHM-029 for Acute Myeloid Leukemia
Key milestone marks transition of CHARM into a clinical stage company Initial data anticipated in 2027 LONDON – 7 October 2026 -- CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage biotechnology company addressing resistance in acute myeloid leukemia (AML) with a best-in-class menin inhibitor, today announces it has initiated dosing and fully enrolled the first cohort in its Phase I/II clinical trial of CHM-029 in patients with AML. This is the first example of a molecule designed usi
Kane Biotech to Present Clinical Data and Showcase revyve® Product Line at SAWC Fall 2026
Company to engage with wound-care professionals and meet with existing and prospective distribution partners WINNIPEG, Manitoba, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it will attend the Symposium on Advanced Wound Care (“SAWC”) Fall 2026, taking place October 15–18, 2026, in Las Vegas, Nevada. O
Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases
Financing co-led by Nextech Invest and Norwest, with participation from new and existing investors Proceeds to support clinical development of MPT-062, an oral first-in-class T cell modulator, to begin in 2027 WATERTOWN, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Matchpoint Therapeutics, a biotechnology company pioneering the discovery of precision covalent medicines, today announced the successful closing of a $150 million Series B financing. The financing was co-led by Nextech Invest and Norwest
MUVON Therapeutics Reports Positive 12-Month Phase 2 Follow-up Data Confirming Durable Efficacy of its First-in-Class Muscle Regeneration Therapy in Stress Urinary Incontinence
Zurich, Switzerland, October 7, 2026 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive 12-month interim results from the Long-Term Follow-Up Study of the Phase 2 clinical trial SUISSE-MPC2 ( NCT05534269 ), demonstrating durable, sustained and clinically relevant bladder health benefits in patients treated with its novel proprietary muscle precursor cell (MPC)-based tissue-engineered therapy for female stress urinary incontinence (SUI). SUI represents a high unmet
Lenovo Takes CES 2027 Keynote to New Heights with Immersive Experience at Sphere
Lenovo brings Tech World @ CES with Hybrid AI through an experience unlike anything CES audiences have seen before ARLINGTON, Va. , Oct. 7, 2026 -- The Consumer Technology Association (CTA) , owner and producer of CES , announces that Lenovo will bring its flagship Tech World event to CES, for a keynote experience like no other at Sphere in Las Vegas . Lenovo will host Tech World @ CES on Wednesday, Jan. 6, 2027, with Chairman and CEO Yuanqing Yang taking the stage alongside other human AI leaders at 5 pm PT for an unforgettable CES keynote with immersive visuals and audio.
Report: AI Overspending Ignored by C-Suite while Political Uncertainty Threatens Q3 Forecasts
83% of organizations say consumption-based AI costs have exceeded expectations, yet finance leaders remain unbothered as the technology reshapes roles and increases executive reporting time PARIS , October 7, 2026 -- New findings from Pigment s Q3 CFO Index reveal a widening disconnect between business performance and confidence as political uncertainty rises and AI introduces new, unpredictable costs. Among 2,000 CFOs and finance executives surveyed across the US, UK, France, and Germany, just 4% report falling revenue, yet confidence in their organization s direction declined for the third consecutive quarter as uncertainty increased.
PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy
PARIS, Oct. 07, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical-stage biotech company developing disruptive non-viral vectorized gene therapies with minimally invasive delivery technology, has presented further data from its PST-611 phase I clinical trial (CT1) in patients with advanced dry age-related macular degeneration (AMD), known as geographic atrophy (GA), in an oral presentation at the European Society of Retina Specialists’ 26th Euretina Congress, held 1-
Apollo Clinical Research Conclave 2026 Explores the Future of Integrated Healthcare Innovation
Two-day national conclave brings together 350+ delegates to reimagine futuristic clinical research through innovation, technology, and collaboration NEW DELHI , Oct. 7, 2026 -- Apollo Research & Innovations successfully hosted the 4 th edition of its flagship event, the Apollo Clinical Research Conclave 2026 at Indraprastha Apollo Hospitals, New Delhi, under the theme Reimagining Futuristic Clinical Research for Integrated Healthcare Innovations . The two-day conclave brought together 350+ delegates from the fields of Clinical Research, Healthcare, Pharmaceuticals, Hospitals, CRO s, Medical Devices, Regulators, Academia and Innovation Ecosystem.
OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks
DUBAI, United Arab Emirates, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Microdomain Science connects differentiated assets across personalized immuno-oncology, acellular biotechnology, MedTech and precision nutrition as OGRD Alliance expands international market access, asset-specific licensing, commercialization and strategic-capital initiatives. OGRD Alliance L.L.C-FZ announced a new phase in the international development of PLPC Platform following the public listing with Singapore’s Health Sciences Au
Thoughtworks Global CIO Survey 2026: India's CIOs hold more influence over AI decisions, but accountability is outpacing control
India records the highest reliance on central IT for AI decision-making among 10 markets surveyed, even as CIOs face growing accountability for privacy and security outcomes they cannot fully influence BENGALURU, India and CHICAGO , Oct. 7, 2026 -- India s enterprise AI landscape is entering a new phase: technology leadership has a stronger grip on AI decision-making than in any other market surveyed, while Indian CIOs also report high visibility into independently adopted AI tools. Yet that visibility and influence do not necessarily translate into control over outcomes, as accountability for privacy and security increasingly extends beyond the boundaries of their authority.
izmo Microsystems and IIT Madras Enter Phase II of ₹99.94 Crore MeitY-Sanctioned Silicon Photonics Program
Five-year CPPICS SPECTRA program targets 1.6 Tbps optical transceivers, co-packaged optics, quantum communications and photonic AI BENGALURU, India , Oct. 7, 2026 -- izmo Limited (NSE: IZMO) (BSE: 532341) today announced that its semiconductor subsidiary, izmo Microsystems Pvt. Ltd., has entered into a Memorandum of Understanding with the Indian Institute of Technology Madras (IIT Madras) for Phase II of the Centre for Programmable Photonic Integrated Circuits and Systems (CPPICS). The Phase II program, titled Silicon Photonics Enabled Cutting-edge Technology Research and Applications (SPECTRA) , has been sanctioned by the Ministry of Electronics and Information Technology (MeitY), Government of India, with a total project outlay of 99.94 crore. The five-year program includes a MeitY contribution of 97.54 crore and a 2.40 crore cash and in-kind commitment from izmo Microsystems.
Chandigarh University Signs MoU with 247VC to Create Investment Opportunities for Quantum and Deep-Tech Startups
Chandigarh University s CUBIC becomes India s First University-Led Quantum Incubator for Deep-Tech Startups, Signs MoU with 247VC NEW DELHI , Oct. 7, 2026 -- Chandigarh University s CUBIC, India s first university-led quantum incubator for deep-tech startups became an academic and incubation partner for PRAGATI Q-Foundry 2026, a national initiative of the Ministry of Science and Technology, aimed at accelerating the development and commercialization of quantum technologies, and signed a Memorandum of Understanding (MoU) with 247VC Investment Trust which is a leading Indian venture capital firm on the sidelines of the PRAGATI Q-FOUNDRY 2026 NQM Co-development and Venture Partnership Meet held on September 29 30 in New Delhi.
Kaizen Analytix Becomes Kaizen Global to Reflect Expanding Global Footprint and Services Capabilities
New Name and Refreshed Brand Identity Reflect the Company s Evolution Across AI, Data, Technology and Global Delivery ATLANTA , Oct. 7, 2026 -- Kaizen Analytix LLC, a global provider of AI, data analytics and technology services and solutions, today announced that it is changing its name to Kaizen Global LLC. The new name reflects the company s continued expansion across geographies, capabilities and industries, including the recent acquisition of Nihon Technology, growth of its global delivery model and expanded portfolio of AI and technology services.
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand REYKJAVIK, Iceland, and SEOUL, South Korea (October 6, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and LOTTE Biologics, a contract developmen
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
New preclinical data further characterizes EQ504’s coordinated effects across epithelial and immune compartments in intestinal inflammation LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in a poster at the 50 th Anniversary La Jolla Immunology Conference , taking place Oct
Remix Therapeutics™ Appoints Michael Landsittel to Board of Directors
WATERTOWN, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Michael Landsittel to its Board of Directors. “We are delighted to welcome Michael to the Remix Board of Directors,” said Pete Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics. “His proven track record of
Repligen Completes Acquisition of BioLife Solutions
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. “We are excited to welcome BioLife team members to Repligen,” said Olivier Loe
INmune Bio to Attend the 2026 Maxim Growth Summit
BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. INmune Bio
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC) MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) , a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately $5.6 million private investment in public equity (PIPE) financing throu
Cambridge Heartwear Awarded £184 Million NHS Tender for World's First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable
CAMBRIDGE, England , Oct. 6, 2026 -- Cambridge Heartwear Limited ( www.camheartwear.com ) has secured a landmark 184 million tender with the National Health Service (NHS) of the UK for HeartSense , the world s first medical-grade, multi-channel, portable, wirelessly charged ECG wearable straight to one s mobile phone , representing a significant advancement in global Medical technology, AI application and cardiovascular diagnostics. The agreement with the UK National Health Service Supply chain enables the deployment of advanced cardiac monitoring technology across primary and secondary care and civil service departments, empowering patients to diagnose heart rhythm problems whenever and wherever they are to prevent heart failure and strokes earlier, reduce waiting times and support a more preventative approach to Heart Disease, which can take place in the comfort of their own homes.
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy Appointment strengthens commercial and development leadership as PMN310 advances toward 12-month topline data expected in Q1 2027 CAMBRIDGE, Mass.,, Oct. 06, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company developing therapeutics targeting toxic
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
European Affiliate, based in Amsterdam, to support upcoming marketing authorization submissions, OCU410 Phase 3 development program, and potential commercialization in Europe MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to address blindness diseases, today announced the appointment of Jolanda Crombach, MSc PharmD, as General Manager of the Company’s E
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) , and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce it has signed a letter of intent with Novatech, widely recognized as the premier Asia-Pacific (APAC) full-service clinical CRO for smal